HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons

被引:5
作者
Jiang, Fengxian [1 ,2 ]
Lai, Jingjiang [1 ,2 ]
Zhuo, Xiaoli [1 ,3 ]
Liu, Lei [1 ,3 ]
Yang, Yucheng [4 ]
Zhang, Junlei [5 ]
Zhao, Jing [1 ,3 ]
Xu, Wei [6 ]
Wang, Jingliang [1 ,2 ]
Wang, Cuiyan [4 ]
Fu, Guobin [1 ,6 ,7 ]
机构
[1] Shandong First Med Univ, Shandong Prov Hosp, Dept Oncol, Jinan, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Clin Med Coll 2, Jinan, Peoples R China
[3] Shandong First Med Univ, Shandong Acad Med, Clin Med Coll, Jinan, Peoples R China
[4] Shandong First Med Univ, Shandong Prov Hosp, Dept Radiol, Jinan, Peoples R China
[5] Shandong Univ, Shandong Prov Hosp, Dept Pathol, Jinan, Peoples R China
[6] Shandong Univ, Shandong Prov Hosp, Dept Oncol, Jinan, Peoples R China
[7] Shandong First Med Univ, Shandong Prov Hosp, Dept Oncol, 324 Jingwu Weiqi Rd, Jinan, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
human epidermal growth factor receptor 2-positive breast cancer; pyrotinib; progress rapidly; resistance; tyrosine kinase inhibitors; trastuzumab; MOLECULAR PORTRAITS; TRASTUZUMAB; CHEMOTHERAPY; SURVIVAL; PREDICT; P53;
D O I
10.1097/CAD.0000000000001506
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Approximately 15-20% of the patients with breast cancer overexpress human epidermal growth factor receptor 2 (HER2). HER2-positive breast cancer is highly aggressive and has a high relapse rate, suggesting that it is prone to and progresses rapidly after drug resistance. Pyrotinib resistance and changes in patients' conditions after drug resistance are challenging clinical issues and require medical attention. Recently, there are few clinical reports on changes in patients' conditions after pyrotinib resistance. We report a case of a 46-year-old patient with HER2-positive breast cancer who developed resistance to pyrotinib and rapidly progressed to uncontrolled liver failure in less than a week. To elucidate the cause of the rapid progression, we collected samples of the patient's ascites and performed next-generation sequencing (NGS). On the basis of the NGS results, we speculated that the rapid progression after pyrotinib resistance might be due to RET gene fusion and TP53 gene mutations. Therefore, this case report aims to alert oncologists that patients with HER2-positive breast cancer, who are resistant to pyrotinib or other targeted drugs, could experience rapid or even flare-up progression and that RET gene fusion and TP53 gene mutations might be potential causes.(c) 2023 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:1196 / 1201
页数:6
相关论文
共 35 条
[1]   Pyrotinib: First Global Approval [J].
Blair, Hannah A. .
DRUGS, 2018, 78 (16) :1751-1755
[2]   11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].
Cameron, David ;
Piccart-Gebhart, Martine J. ;
Gelber, Richard D. ;
Procter, Marion ;
Goldhirsch, Aron ;
de Azambuja, Evandro ;
Castro, Gilberto, Jr. ;
Untch, Michael ;
Smith, Ian ;
Gianni, Luca ;
Baselga, Jose ;
Al-Sakaff, Nedal ;
Lauer, Sabine ;
McFadden, Eleanor ;
Leyland-Jones, Brian ;
Bell, Richard ;
Dowsett, Mitch ;
Jackisch, Christian .
LANCET, 2017, 389 (10075) :1195-1205
[3]   Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J].
Carey, Lisa A. ;
Perou, Charles M. ;
Livasy, Chad A. ;
Dressler, Lynn G. ;
Cowan, David ;
Conway, Kathleen ;
Karaca, Gamze ;
Troester, Melissa A. ;
Tse, Chiu Kit ;
Edmiston, Sharon ;
Deming, Sandra L. ;
Geradts, Joseph ;
Cheang, Maggie C. U. ;
Nielsen, Torsten O. ;
Moorman, Patricia G. ;
Earp, H. Shelton ;
Millikan, Robert C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2492-2502
[4]   Tyrosine Kinase Inhibitors for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Is Personalizing Therapy Within Reach? [J].
Chien, Amy Jo ;
Rugo, Hope S. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) :3089-+
[5]  
Dai J., 2020, Medicine (Baltim), V99, pe20809e20809
[6]   Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib-Irinotecan Combo: A Case Study [J].
Ding, Kailin ;
Chen, Xian ;
Li, Yong ;
Li, Wenzhu ;
Ye, Yongsong ;
He, Tingting ;
Wang, Wenjing ;
Zhang, Haibo .
ONCOTARGETS AND THERAPY, 2021, 14 :545-550
[7]  
Duman BB, 2013, J BUON, V18, P44
[8]   Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival [J].
Fan, Y. ;
Wang, Y. ;
He, L. ;
Imani, S. ;
Wen, Q. .
ESMO OPEN, 2021, 6 (04)
[9]  
Geisler S, 2003, CLIN CANCER RES, V9, P5582
[10]   TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer [J].
Grote, Isabel ;
Bartels, Stephan ;
Kandt, Leonie ;
Bollmann, Laura ;
Christgen, Henriette ;
Gronewold, Malte ;
Raap, Mieke ;
Lehmann, Ulrich ;
Gluz, Oleg ;
Nitz, Ulrike ;
Kuemmel, Sherko ;
Zu Eulenburg, Christine ;
Braun, Michael ;
Aktas, Bahriye ;
Grischke, Eva-Maria ;
Schumacher, Claudia ;
Luedtke-Heckenkamp, Kerstin ;
Kates, Ronald ;
Wuerstlein, Rachel ;
Graeser, Monika ;
Harbeck, Nadia ;
Christgen, Matthias ;
Kreipe, Hans .
CANCER MEDICINE, 2021, 10 (23) :8581-8594